Go to the Globe and Mail homepage

Jump to main navigationJump to main content

AdChoices
The headquarters of Valeant Pharmaceuticals International Inc., seen in Laval, Quebec November 9 2015. (CHRISTINNE MUSCH/REUTER)
The headquarters of Valeant Pharmaceuticals International Inc., seen in Laval, Quebec November 9 2015. (CHRISTINNE MUSCH/REUTER)

Investors take aim at bloated share grants to CEOs Add to ...

Subscribers Only

The 2017 TSX Composite Compensation & Performance Report is available for purchase here.

Some major shareholders are growing frustrated with the way companies are doling out share units as a major part of CEO pay, voting against pay packages at several large companies this year over concerns about equity grants that are oversized or poorly linked to performance.

Report Typo/Error

Follow on Twitter: @JMcFarlandGlobe

 

More Related to this Story

Next story

loading

Trending

loading

Most popular videos »

More from The Globe and Mail

Most popular